| 000 | 01722 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516091451.0 | ||
| 264 | 0 | _c20121203 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1473-5741 | ||
| 024 | 7 |
_a10.1097/CAD.0b013e32835396d4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avon Gruenigen, Vivian E | |
| 245 | 0 | 0 |
_aToxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. _h[electronic resource] |
| 260 |
_bAnti-cancer drugs _cAug 2012 |
||
| 300 |
_a724-30 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAnemia _xchemically induced |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDiarrhea _xchemically induced |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeutropenia _xchemically induced |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTopoisomerase I Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aTopotecan _xtherapeutic use |
| 650 | 0 | 4 |
_aUterine Neoplasms _xdrug therapy |
| 700 | 1 | _aFrasure, Heidi E | |
| 700 | 1 | _aSmith, Deborah A | |
| 700 | 1 | _aFusco, Nancy L | |
| 700 | 1 | _aEaton, Susan M | |
| 700 | 1 | _aDeBernardo, Robert L | |
| 700 | 1 | _aHeugel, Anne M | |
| 700 | 1 | _aWaggoner, Steven E | |
| 773 | 0 |
_tAnti-cancer drugs _gvol. 23 _gno. 7 _gp. 724-30 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/CAD.0b013e32835396d4 _zAvailable from publisher's website |
| 999 |
_c21752013 _d21752013 |
||